{
    "root": "551d4eda-5c34-4a2a-89f8-661372342fe5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fruzaqla",
    "value": "20250306",
    "ingredients": [
        {
            "name": "FRUQUINTINIB",
            "code": "49DXG3M5ZW"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C YELLOW NO. 5",
            "code": "I753WB2F1M"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        }
    ],
    "indications": "fruzaqla indicated treatment adult patients metastatic colorectal cancer ( mcrc ) previously treated fluoropyrimidine\u2011 , oxaliplatin\u2011 , irinotecan\u2011based chemotherapy , anti\u2011vegf therapy , , ras wild\u2011type medically appropriate , anti-egfr therapy .",
    "contraindications": "recommended dose fruzaqla 5 mg orally daily , without food first 21 days 28-day cycle . ( 2.1 )",
    "warningsAndPrecautions": "supplied capsule strength description package configuration ndc number 1 mg size 3 hard gelatin capsule yellow opaque cap white opaque body , imprinted \u201c hm013 \u201d \u201c 1 mg \u201d body black ink white high-density polyethylene ( hdpe ) bottle child-resistant closure packaged carton . bottle contains 21 capsules . 63020-210-21 5 mg size 1 hard gelatin capsule red opaque cap white opaque body , imprinted \u201c hm013 \u201d \u201c 5 mg \u201d body black ink 63020-225-21",
    "adverseReactions": "none .",
    "indications_original": "FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine\u2011, oxaliplatin\u2011, and irinotecan\u2011based chemotherapy, an anti\u2011VEGF therapy, and, if RAS wild\u2011type and medically appropriate, an anti-EGFR therapy.",
    "contraindications_original": "The recommended dose of FRUZAQLA is 5 mg orally once daily, with or without food for the first 21 days of each 28-day cycle. ( 2.1 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           Capsule Strength\n                           Description\n                           Package Configuration\n                           NDC Number\n                        \n                     \n                     \n                        \n                           1 mg\n                           Size 3 hard gelatin capsule with yellow opaque cap and white opaque body, imprinted with \u201cHM013\u201d over \u201c1 mg\u201d on the body in black ink\n                           White high-density polyethylene (HDPE) bottle with child-resistant closure packaged in a carton. Each bottle contains 21 capsules.\n                           63020-210-21\n                        \n                        \n                           5 mg\n                           Size 1 hard gelatin capsule with a red opaque cap and white opaque body, imprinted with \u201cHM013\u201d over \u201c5 mg\u201d on the body in black ink\n                           63020-225-21",
    "adverseReactions_original": "None."
}